PAM THERAGNOSTICS GMBH
PAM Theragnostics GmbH is a preclinical-stage German biotech startup developing a PEG-PAM enzyme therapy and companion biomarker-guided diagnostic tools for early detection and prevention of Alzheimer's disease, targeting First-In-Human trials by 2027.
- Company typePrivate
- Founded2020
- HeadquartersHennigsdorf, Germany
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What PAM THERAGNOSTICS GMBH does
PAM Theragnostics GmbH is a privately held German biotech startup founded in 2020 and headquartered in Hennigsdorf, Brandenburg, near Berlin. The company is developing a combined therapeutic and diagnostic ("theragnostics") platform aimed at the vascular contributions to Alzheimer's disease (AD), with the Peptidylglycine alpha-amidating monooxygenase (PAM) enzyme serving as its central therapeutic target. Its core technology proposition is that supplementing or compensating for insufficient endogenous PAM activity can reactivate peptide hormones with vascular protective functions and thereby counteract blood-brain barrier (BBB) damage implicated in AD progression. The company's flagship asset is a disease-modifying PEG-PAM drug substance for neurovascular indications, paired with companion biomarker-guided tools intended for early detection and prediction of Alzheimer's onset. Its scientific approach draws on insights derived from the healthy centenarian population of the Cilento region.
The company operates with a lean core team of approximately four members, including a CEO with a track record of founding and operating prior biotechs (sphingotec, 4TEEN4, Adrenomed AG), a CSO with structural biology expertise, a Head of Operations, and an R&D scientist. It is currently in the preclinical stage, is initiating GMP production, and has publicly targeted First-In-Human clinical entry by 2027. To extend its R&D capacity, the company maintains strategic academic and clinical collaborations with Lund University, Sapienza Università di Roma, INSERM/Université de Paris Cité, University of Tasmania, University of Groningen, Universitätsklinikum Aachen, and Fraunhofer ISC.
PAM Theragnostics is pre-revenue and has no commercial products, distribution channels, or marketing programs. Its activities to date have been financed primarily through a €1.5 million investment from Brandenburg Kapital in January 2022 and non-dilutive co-financing from the European Regional Development Fund (EFRE) and the Federal State of Brandenburg under the ProFIT Brandenburg program (Grant Nos. 80256636, 80256637). Future monetization, when it occurs, is expected to flow from licensing or commercialization of its PEG-PAM therapeutic and companion diagnostic assets rather than from current product sales, with end-customers ultimately being AD patients and healthcare systems.
PAM THERAGNOSTICS GMBH firmographics
Firmographics- Name
- PAM THERAGNOSTICS GMBH
- Legal name
- PAM Theragnostics GmbH
- Website
- https://pam-t.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- PAM Theragnostics GmbH is a preclinical-stage German biotech startup developing a PEG-PAM enzyme therapy and companion biomarker-guided diagnostic tools for early detection and prevention of Alzheimer's disease, targeting First-In-Human trials by 2027.
- Ownership category
- akta.pro rank
PAM THERAGNOSTICS GMBH industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK)
- akta.pro secondary industry
- Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers) (HLAAAMAD)
Keywords
Where PAM THERAGNOSTICS GMBH is headquartered
LocationHeadquarters
- HQ city
- Hennigsdorf
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
PAM THERAGNOSTICS GMBH business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Others
Revenue model
- Therapeutic Development: Pre-revenue company developing preventive therapy for Alzheimer's Disease. No commercial products yet. Anticipates First-In-Human phase by 2027.
Go-to-market motion1 record
PAM THERAGNOSTICS GMBH product offering
Product offeringCore offering
PAM Theragnostics GmbH develops a disease-modifying PEG-PAM drug candidate targeting the Peptidylglycine alpha-amidating monooxygenase (PAM) enzyme to activate vascular protective peptide hormones and counteract Blood-Brain Barrier damage in Alzheimer's disease. The company is also developing companion diagnostic tools and biomarker-guided therapy for early detection and prediction of Alzheimer's disease, with a focus on vascular contributions to neurodegeneration. Both offerings are currently in preclinical development, with First-In-Human phase anticipated by 2027.
Product overview
PAM Theragnostics GmbH is a biotech startup established in 2020 developing a unified therapeutic and diagnostic approach for Alzheimer's disease. The company operates two integrated offerings: PAM Therapy (a PEG-PAM drug candidate targeting the PAM enzyme to activate protective vascular peptide hormones) and companion diagnostic tools for early detection and prediction of Alzheimer's. The company is transitioning from preclinical research toward GMP production, with a First-In-Human phase anticipated by 2027.
Differentiator
Problem solved
Functional benefit
Products and services
- PAM Therapy (PEG-PAM Drug Candidate) A disease-modifying PEG-PAM drug candidate targeting the Peptidylglycine alpha-amidating monooxygenase (PAM) enzyme to activate peptide hormones with vascular protective functions and counteract Blood-Brain Barrier damage in Alzheimer's disease. Currently in preclinical development.
- Alzheimer's Disease Diagnostic Tools
Quantifiable outcome
- First-In-Human phase by 2027
- +1 more outcomes
Companies that use PAM THERAGNOSTICS GMBH
Customer profileSegments2 records
Ideal customer profiles2 records
PAM THERAGNOSTICS GMBH technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
PAM THERAGNOSTICS GMBH partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core.
- Lund UniversitycoreAcademic collaboration with Prof. Lars Edvinsson and Prof. Olle Melander. Part of strategic research partnerships for PAM enzyme research and Alzheimer's disease studies.
- Sapienza Università di RomacoreCollaboration with Prof. Salvatore Di Somma for research on PAM enzyme and neurovascular conditions.
- INSERM, Université de Paris CitécoreResearch collaboration with Prof. Alexandre Mebazaa on PAM enzyme and peptide hormone research.
- University of TasmaniacoreCollaboration with Dr. Dino Premilovac on vascular research related to PAM enzyme.
- University of GroningencoreAcademic partnership with Prof. Stephan Bakker for PAM enzyme research.
- Universitätsklinikum AachencoreClinical research collaboration with Dr. Christoph Thiele on PAM enzyme studies.
- Fraunhofer-Institut für Silicatforschung ISCcoreResearch partnership with Dr. Appelt-Menzel for PAM enzyme and therapeutic development.
Scale indicators6 records
Recent moves5 records
Expansion highlights5 records
PAM THERAGNOSTICS GMBH competitors and assessment
Company assessmentBroad incumbents
- Biogen Inc. Large US biopharmaceutical company and market leader in Alzheimer's disease with Leqembi (lecanemab) co-developed with Eisai. Comparable as the dominant established player whose regulatory, commercial, and clinical infrastructure defines the competitive landscape PAM Theragnostics would enter.
- Eisai Co., Ltd. Japan-headquartered global pharma co-developer of Leqembi and long-standing leader in Alzheimer's disease R&D. Comparable as a broad incumbent shaping AD clinical practice, regulatory pathways, and partnership opportunities for emerging AD biotechs.
Direct peers
- Anavex Life Sciences Corp. US clinical-stage biotech developing treatments for Alzheimer's and other neurodegenerative diseases via small-molecule sigma receptor agonists. Comparable as a small-cap AD biotech pursuing non-amyloid mechanisms.
- BioArctic AB: Swedish clinical-stage biotech developing disease-modifying treatments and biomarkers for Alzheimer's and other CNS diseases. Highly comparable as a Europe-based, small-cap neurodegenerative biotech with a similar dual diagnostic/therapeutic ambition.
- Cassava Sciences, Inc. US clinical-stage biotech focused on Alzheimer's disease with both a small-molecule therapeutic (simufilam) and a diagnostic (SavaDx). Closely comparable theragnostic-style dual program targeting AD.
- AC Immune SA: Swiss clinical-stage biopharmaceutical company focused on precision medicine for Alzheimer's and neurodegenerative diseases, with a pipeline spanning vaccines, antibodies, and diagnostics. Directly comparable therapeutic-diagnostic positioning and European preclinical-to-clinical biotech profile.
- Alector, Inc. US clinical-stage biotech developing immuno-neurology therapies for Alzheimer's and frontotemporal dementia. Comparable as a neurodegeneration-focused biotech with novel mechanism-of-action programs aimed at disease modification.
- Prothena Corporation: Ireland/US-based clinical-stage biotech developing protein-targeted therapies for neurodegenerative diseases including Alzheimer's. Comparable as an AD-focused biotech pursuing mechanism-distinct disease-modifying approaches.
Emerging players
- Cogstate Ltd. Australia-based neuroscience-focused digital health company developing cognitive assessment tools, including those used in Alzheimer's clinical trials. Comparable as a neuro-diagnostic technology provider serving the AD market.
- Alzheon, Inc. US clinical-stage biotech developing an oral small-molecule therapy (ALZ-801) targeting Alzheimer's. Comparable as a small AD-focused biotech with a differentiated mechanism and biomarker-guided development.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
PAM THERAGNOSTICS GMBH social profiles
Digital presencePAM THERAGNOSTICS GMBH financial estimates
Financial estimateRevenue estimate
Valuation estimate
PAM THERAGNOSTICS GMBH leadership team
Management profileNumber of profiles
Profiles4 records
PAM THERAGNOSTICS GMBH funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PAM THERAGNOSTICS GMBH M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PAM THERAGNOSTICS GMBH
What does PAM THERAGNOSTICS GMBH do?
PAM Theragnostics GmbH develops a disease-modifying PEG-PAM drug candidate targeting the Peptidylglycine alpha-amidating monooxygenase (PAM) enzyme to activate vascular protective peptide hormones and counteract Blood-Brain Barrier damage in Alzheimer's disease. The company is also developing companion diagnostic tools and biomarker-guided therapy for early detection and prediction of Alzheimer's disease, with a focus on vascular contributions to neurodegeneration. Both offerings are currently in preclinical development, with First-In-Human phase anticipated by 2027.
Is PAM THERAGNOSTICS GMBH a public or private company?
PAM THERAGNOSTICS GMBH is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was PAM THERAGNOSTICS GMBH founded?
PAM THERAGNOSTICS GMBH was founded in 2020. It employs 1 to 10 people.
Where is PAM THERAGNOSTICS GMBH based?
PAM THERAGNOSTICS GMBH is headquartered in Hennigsdorf, Germany, in the Europe region.
How does PAM THERAGNOSTICS GMBH make money?
One revenue line is on record: therapeutic Development.
Who are PAM THERAGNOSTICS GMBH's main competitors?
Broad incumbents on record are Biogen Inc. and Eisai Co., Ltd.. Direct peers are Anavex Life Sciences Corp., BioArctic AB, Cassava Sciences, Inc., AC Immune SA, Alector, Inc. and Prothena Corporation. Emerging players are Cogstate Ltd. and Alzheon, Inc..
Does PAM THERAGNOSTICS GMBH have an API?
No public API is recorded for PAM THERAGNOSTICS GMBH.
What industry is PAM THERAGNOSTICS GMBH in?
PAM THERAGNOSTICS GMBH's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAK, In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy), with a secondary code of HLAAAMAD, Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers). Its NAICS code is 541714 and its SIC code is 2836.